Scisparc announced positive interim results meeting primary endpoints at phase iia study in alzheimer's disease patients with agitation

Tel-aviv, nov. 07, 2022 (globe newswire) -- scisparc ltd. (nasdaq: sprc), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “company” or “scisparc”), today announced positive interim results from its phase iia trial of sci-110 in patients with alzheimer's disease (“ad”) and agitation. agitation manifests in the course of ad progression in almost all affected patients, increasing patients' suffering and burden of care.
SPRC Ratings Summary
SPRC Quant Ranking